Polarean Imaging (POLX) , a UK-based medical imaging technology company, announced that the University of Missouri Health Care is set to begin clinical imaging with Polarean's XENOVIEW MRI technology, after an upgrade to its Radiology department's polariser system, and a delivery of a gas blend cylinder the produce the agent.
XENOVIEW is the first and only inhaled contrast agent approved by the US Food and Drug Administration for use with magnetic resonance imaging (MRI) for the evaluation of lung ventilation in adults and paediatric patients aged 12 years and older.
MU Health Care's Department of Radiology expects to begin the scanning of hospital clinic patients imminently.
XENOVIEW is an innovative technology that enables visualisation of lung ventilation without exposing patients to ionising radiation and its associated risks. The Polarean HPX Hyperpolarisation System creates a dose of XENOVIEW that is administered in a single 10 to 15 second breath-hold MRI procedure.
Christopher von Jako, CEO of Polarean, said: "I am delighted that MU Health Care has upgraded its polariser system for clinical use, and will imminently begin clinical scanning for pulmonary patients. This represents further execution of our strategic plan to convert existing XENOVIEW research sites, whilst in parallel looking to secure new installations."
View from Vox
Today's news marks a key milestone in the execution of Polarean’s commercial plan, taking steps towards filling the gap in non-invasive diagnostic technology for chronic lung disease patients.
Polarean’s announcement builds on recent news in May when the first patient in the US underwent a clinical scan using XENOVIEW. Shortly after, the company announced that Philips' MR 7700 MRI scanner was to be combined with XENOVIEW, showcasing the capability to enhance pulmonary imaging. Polarean's collaboration with a major industry player marks a significant milestone, positioning the company for increased visibility and recognition within the medical imaging market.
XENOVIEW meets the demand for non-invasive diagnostic technology, offering regional lung ventilation maps for improved healthcare outcomes in patients with chronic lung disease. With the market for contrast media valued at $4.04 billion in 2021 and projected to grow at a CAGR of 3.33% from 2022 to 2030, the need for diagnostic imaging procedures, including XENOVIEW, is on the rise due to the growing prevalence of long-term diseases.
Polarean remains well-funded, with a higher-than-expected $16.5m in the bank at the end of 2022, positioning it well to continue advancing XENOVIEW across various stages of commercialisation in the US and beyond.
Follow Polarean Imaging for more News and Updates: